OA: Bevacizumab in ovarian cancer: A critical review of phase III studies Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, November 17, 2016

OA: Bevacizumab in ovarian cancer: A critical review of phase III studies



open access

Indeed, many open questions are emerging about the role of BV in OC and many doubts still deserve clear explanations. [77].
Should BV be used alone or associated with chemotherapy? Is use of BV as single-agent less toxic in all the patients? Is it extended and maintenance therapy an effective part of front-line treatment?
Regarding duration of BV, an extended therapy could be associated with an improved clinical benefit but, at same time, with higher costs and greater toxicity.

0 comments :

Post a Comment

Your comments?